The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population
Abstract
Objective: To prospectively determine the prevalence and annual incidence of hepatocellular carcinoma in hepatitis B carriers in a heterogeneous urban North American population and to assess the diagnostic accuracy of tests used for screening for this cancer. Design: Prospective cohort study of 1,069 chronic carriers of hepatitis B virus using screening with α-fetoprotein alone or in combination with ultrasonography every 6 months. Results: The mean age of the cohort was 39 ± 12 years (± SD), 65% were men, 71% were Asians. At the first screening visit, serum α-fetoprotein was ≥ 20 μg/L in 4%. In those subjects who were also screened by ultrasonography during the first visit, 9% were found to have focal lesions. Only 3 subjects were found to have hepatocellular carcinoma at the first screening, giving a prevalence of 281/100,000 chronic carriers of hepatitis B virus. The cohort was followed for 2,340 person-years (mean, 26 months follow-up, with a range from 6 to 60 months). During this period, 11 more subjects, 10 men and 1 woman, were diagnosed to have hepatocellular carcinoma (annual incidence, 470/100,000). In men only, the annual incidence was 657/100,000. During the study, 5 subjects died from hepatocellular carcinoma (annual mortality rate, 214/100,000). Sensitivity and specificity of serum α-fetoprotein >20 μg/L were 64.3% and 91.4%, respectively. For ultrasonography, sensitivity was 78.8% and specificity 93.8%. Conclusions: These data suggest that the incidence and prevalence of hepatocellular carcinoma in hepatitis B carriers in our area, an urban North American setting, are as high as in countries where hepatitis B is endemic. Current screening tests have significant false-positive and false-negative rates, raising questions about the cost-benefit of screening for hepatocellular carcinoma in our study population. (Hepatology 1995;22:432-438.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
Hepatitis B virus.The major etiology of hepatocellular carcinoma
Beasley, R. P. (1988) · Cancer · doi:10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j · Cited by 1,280
Hepatocellular Carcinoma in Italian Patients with Cirrhosis
Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M. F., Piva, A., Di Carlo, V., & Dioguardi, N. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251002 · Cited by 813
McMahon, B. J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.5.1051 · Cited by 273
Shinagawa, T., Ohto, M., Kimura, K., Tsunetomi, S., Morita, M., Saisho, H., Tsuchiya, Y., Saotome, N., Karasawa, E., & Miki, M. (1984) · PubMed · Cited by 268
Shinagawa, T., Onto, M., Kimura, K., Tsunetomi, S., Morita, M., Saisho, H., Tsuchiya, Y., Saotome, N., Karasawa, E., Miki, M., et al. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80020-7 · Cited by 236
Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma.
Chen, D., Sung, J., Sheu, J., Lai, M., How, S.-W., Hsu, H., Lee, C., & Wei, T. (1984) · PubMed · Cited by 202
Self-citationMcMahon, B. J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390170087019 · Cited by 201
The role of chronic viral hepatitis in hepatocellular carcinoma in the United States.
Bisceglie, A. M. D., Order, S. E., Klein, J., Waggoner, J. G., Sjögren, M. H., Kuo, G. C., Houghton, M., Choo, Q. L., & Hoofnagle, J. H. (1991) · PubMed · Cited by 150
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationLok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationRandomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Hepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
Metadata
- Authors
- Sherman, M., Peltekian, K. M., & Lee, C.
- Venue
- Hepatology
- Published
- 1995-08
- Volume
- 22
- Issue
- 2
- Pages
- 432-438
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2113410022
- Cited by
- 357
- References
- 17
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. https://app.cochat.ai/papers/10.1002/hep.1840220210
- The paper
- Sherman, M., Peltekian, K. M., & Lee, C. (1995). Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. https://doi.org/10.1002/hep.1840220210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.